Verastem Oncology: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Use dmy dates|date=October 2023}} | |||
{{Refimprove|date=October 2023}} | |||
[[File:Verastem_Oncology_official_company_logo.png|thumb|right|Verastem Oncology logo]] | |||
Verastem Oncology | '''Verastem Oncology''' is a [[biopharmaceutical]] company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company is headquartered in [[Needham, Massachusetts]], [[United States]]. | ||
== | ==History== | ||
Verastem Oncology was founded in 2010 by a group of scientists and entrepreneurs, including [[Robert Weinberg]], a prominent cancer researcher. The company was established with the goal of developing therapies targeting cancer stem cells, which are believed to be responsible for tumor growth and recurrence. | |||
Verastem | In 2012, Verastem went public and was listed on the [[NASDAQ]] stock exchange under the ticker symbol VSTM. Over the years, the company has focused on developing treatments for various types of cancer, including [[leukemia]], [[lymphoma]], and [[solid tumors]]. | ||
==Research and Development== | |||
Verastem Oncology's research is centered on targeting cancer stem cells and the tumor microenvironment. The company has developed a pipeline of drug candidates that aim to disrupt the signaling pathways critical for cancer cell survival and proliferation. | |||
One of the company's lead products is [[duvelisib]], an oral dual inhibitor of [[PI3K]]-delta and PI3K-gamma, which has been approved for the treatment of certain types of [[blood cancer]]s. Verastem is also exploring the potential of other compounds in its pipeline for the treatment of solid tumors. | |||
Verastem Oncology has entered into several partnerships | ==Collaborations and Partnerships== | ||
Verastem Oncology has entered into several strategic collaborations and partnerships to advance its research and development efforts. These partnerships have included collaborations with academic institutions, research organizations, and other pharmaceutical companies to enhance the development of its drug candidates. | |||
== Financials == | ==Market and Financials== | ||
As a publicly traded company, Verastem Oncology reports its financial performance on a quarterly basis. The company generates revenue primarily through the sale of its approved products and through licensing agreements with other companies. | |||
==Related pages== | |||
== | |||
* [[Biopharmaceutical]] | * [[Biopharmaceutical]] | ||
* [[ | * [[Cancer treatment]] | ||
* [[ | * [[Pharmaceutical industry]] | ||
==References== | |||
{{Reflist}} | |||
[[Category:Biopharmaceutical companies]] | [[Category:Biopharmaceutical companies]] | ||
[[Category:Companies based in Massachusetts]] | |||
[[Category:Companies based in | |||
[[Category:Companies established in 2010]] | [[Category:Companies established in 2010]] | ||
[[Category: | [[Category:Companies listed on NASDAQ]] | ||
Revision as of 16:12, 9 February 2025
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company is headquartered in Needham, Massachusetts, United States.
History
Verastem Oncology was founded in 2010 by a group of scientists and entrepreneurs, including Robert Weinberg, a prominent cancer researcher. The company was established with the goal of developing therapies targeting cancer stem cells, which are believed to be responsible for tumor growth and recurrence.
In 2012, Verastem went public and was listed on the NASDAQ stock exchange under the ticker symbol VSTM. Over the years, the company has focused on developing treatments for various types of cancer, including leukemia, lymphoma, and solid tumors.
Research and Development
Verastem Oncology's research is centered on targeting cancer stem cells and the tumor microenvironment. The company has developed a pipeline of drug candidates that aim to disrupt the signaling pathways critical for cancer cell survival and proliferation.
One of the company's lead products is duvelisib, an oral dual inhibitor of PI3K-delta and PI3K-gamma, which has been approved for the treatment of certain types of blood cancers. Verastem is also exploring the potential of other compounds in its pipeline for the treatment of solid tumors.
Collaborations and Partnerships
Verastem Oncology has entered into several strategic collaborations and partnerships to advance its research and development efforts. These partnerships have included collaborations with academic institutions, research organizations, and other pharmaceutical companies to enhance the development of its drug candidates.
Market and Financials
As a publicly traded company, Verastem Oncology reports its financial performance on a quarterly basis. The company generates revenue primarily through the sale of its approved products and through licensing agreements with other companies.
Related pages
References
<references group="" responsive="1"></references>
